Premium
Prostatic ductal adenocarcinoma showing Bcl‐2 expression
Author(s) -
TULUNAY ÖZDEN,
ORHAN DİCLEHAN,
BALTACI SÜMER,
GÖǦÜŞ ÇAǦATAY,
MÜFTÜOǦLU YUSUF Z
Publication year - 2004
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2004.00886.x
Subject(s) - medicine , prostatic acid phosphatase , grading (engineering) , adenocarcinoma , prostate , chromogranin a , neuroendocrine differentiation , pathology , pca3 , acid phosphatase , carcinoembryonic antigen , immunohistochemistry , prostate cancer , cancer research , cancer , biology , enzyme , ecology , biochemistry
Prostatic ductal adenocarcinoma represents a rare histological variant of prostatic carcinoma with features of a papillary lesion at cystoscopy. There are conflicts regarding the existence, origin, staging, grading, treatment and clinical behavior of this tumor. The aim of the present study is to examine the expression of Bcl‐2 and p53 in prostatic ductal adenocarcinoma and to evaluate its origin by analyzing prostate specific antigen, prostate specific acid phosphatase, cytokeratins, epithelial membrane antigen and carcinoembryonic antigen expressions. The results confirmed the expression of prostate specific antigen and prostate specific acid phosphatase in prostatic ductal adenocarcinoma. The demonstrated expression of Bcl‐2 was predominant in the better‐differentiated tumor. Bcl‐2 expression appears not to be associated with neuroendocrine differentiation as assessed by chromogranin A reactivity. Thus, the first case of a prostatic ductal adenocarcinoma showing Bcl‐2 expression is presented. The tumor was negative for p53.